FAP neuropathy and emerging treatments (Q34401190)

1 August 2017

title

FAP neuropathy and emerging treatments (English)

1 reference

1 August 2017

4

Vincent Algalarrondo

1 reference

1 August 2017

David Adams

1

1 reference

1 August 2017

Marie Théaudin

series ordinal

2

1 reference

1 August 2017

Cecile Cauquil

series ordinal

3

1 reference

1 August 2017

Michel Slama

series ordinal

5

1 reference

1 August 2017

publication date

1 March 2014

1 reference

Current Neurology and Neuroscience Reports

1 August 2017

published in

1 reference

1 August 2017

volume

14

1 reference

1 August 2017

issue

3

1 reference

1 August 2017

page(s)

435

1 reference

https://scigraph.springernature.com/pub.10.1007/s11910-013-0435-3

1 August 2017

exact match

0 references

cites work

Hereditary and acquired amyloid neuropathies

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Epidemiology of familial amyloid polyneuropathy in Japan: Identification of a novel endemic focus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)-type I in Póvoa do Varzim and Vila do Conde (north of Portugal).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Familial amyloidotic polyneuropathy in Sweden: geographical distribution, age of onset, and prevalence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Late-onset familial amyloid polyneuropathy type I (transthyretin Met30-associated familial amyloid polyneuropathy) unrelated to endemic focus in Japan. Clinicopathological and genetic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Variable presentations of TTR-related familial amyloid polyneuropathy in seventeen patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Genotypic and phenotypic correlation in an Italian population of hereditary amyloidosis TTR-related (HA-TTR): clinical and neurophysiological aids to diagnosis and some reflections on misdiagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Familial amyloidosis with polyneuropathy associated with TTR Ser50Arg mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Clinical presentations and skin denervation in amyloid neuropathy due to transthyretin Ala97Ser.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Regional difference and similarity of familial amyloidosis with polyneuropathy in France

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Transthyretin-related familial amyloidotic polyneuropathy&mdash;Progress in Kumamoto, Japan (1967&ndash;2010)&mdash;

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Usefulness of labial salivary gland biopsy in familial amyloid polyneuropathy Portuguese type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

The molecular biology and clinical features of amyloid neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Familial amyloid polyneuropathy associated with the novel transthyretin variant Arg34Gly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

An amyotrophic lateral sclerosis-like syndrome revealing an amyloid polyneuropathy associated with a novel transthyretin mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Upper limb neuropathy such as carpal tunnel syndrome as an initial manifestation of ATTR Val30Met familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Myocardial muscarinic receptor upregulation and normal response to isoproterenol in denervated hearts by familial amyloid polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

MRI of cardiac involvement in transthyretin familial amyloid polyneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Progression of transthyretin amyloid neuropathy after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

A brief compound test for assessment of autonomic and sensory-motor dysfunction in familial amyloid polyneuropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Safety and efficacy of RNAi therapy for transthyretin amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Risk of transmission of systemic transthyretin amyloidosis after domino liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Amyloid fibril composition as a predictor of development of cardiomyopathy after liver transplantation for hereditary transthyretin amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Variation in amount of wild-type transthyretin in different fibril and tissue types in ATTR amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Impact of antibodies against amyloidogenic transthyretin (ATTR) on phenotypes of patients with familial amyloidotic polyneuropathy (FAP) ATTR Valine30Methionine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-013-0435-3

Genotype, echocardiography, and survival in familial transthyretin amyloidosis.

21 January 2018

1 reference

12 December 2020

Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy.

1 reference

12 December 2020

Description of transthyretin S50A, S52P and G47A mutations in familial amyloidosis polyneuropathy

1 reference

12 December 2020

Comparison between (99m)Tc-diphosphonate imaging and MRI with late gadolinium enhancement in evaluating cardiac involvement in patients with transthyretin familial amyloid polyneuropathy

1 reference

12 December 2020

Transthyretin gene analysis in European patients with suspected familial amyloid polyneuropathy

1 reference

12 December 2020

Symptomatic and provende novoamyloid polyneuropathy in familial amyloid polyneuropathy domino liver recipients

1 reference

12 December 2020

Tyr78Phe Transthyretin Mutation with Predominant Motor Neuropathy as the Initial Presentation

1 reference

12 December 2020

Clinical and genetic findings in eight Israeli patients with transthyretin-associated familial amyloid polyneuropathy

1 reference

12 December 2020

Steady turnover of amyloid fibril proteins in gastric mucosa after liver transplantation in familial amyloid polyneuropathy

1 reference

12 December 2020

Neurophysiological techniques to detect early small-fiber dysfunction in transthyretin amyloid polyneuropathy.

1 reference

12 December 2020

The course and prognostic factors of familial amyloid polyneuropathy after liver transplantation

1 reference

12 December 2020

Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy

1 reference

12 December 2020

Wild-type transthyretin significantly contributes to the formation of amyloid fibrils in familial amyloid polyneuropathy patients with amyloidogenic transthyretin Val30Met

1 reference

12 December 2020

Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy.

1 reference

12 December 2020

Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas

1 reference

12 December 2020

Prophylactic pacemaker implantation in familial amyloid polyneuropathy

1 reference

12 December 2020

Acquired amyloid neuropathy in a Portuguese patient after domino liver transplantation

1 reference

12 December 2020

The diflunisal trial: update on study drug tolerance and disease progression

1 reference

12 December 2020

Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis

1 reference

12 December 2020

Amyloid neuropathy mimicking chronic inflammatory demyelinating polyneuropathy

1 reference

12 December 2020

Clinical and histopathological features of familial amyloidotic polyneuropathy with transthyretin Val30Ala in a Chinese family

1 reference

12 December 2020

Circadian rhythm of blood pressure reflects the severity of cardiac impairment in familial amyloid polyneuropathy

1 reference

12 December 2020

Reduced myocardial 123-iodine metaiodobenzylguanidine uptake: a prognostic marker in familial amyloid polyneuropathy.

1 reference

12 December 2020

Systemic but asymptomatic transthyretin amyloidosis 8 years after domino liver transplantation

1 reference

12 December 2020

A novel variant mutation of transthyretin Ile73Val-related amyloidotic polyneuropathy in Taiwanese

1 reference

12 December 2020

Changes in pathological and biochemical findings of systemic tissue sites in familial amyloid polyneuropathy more than 10 years after liver transplantation.

1 reference

12 December 2020

Overcoming artefact: anticipation in 284 Portuguese kindreds with familial amyloid polyneuropathy (FAP) ATTRV30M.

1 reference

12 December 2020

1 reference

12 December 2020

Reversibility of acquired amyloid polyneuropathy after liver retransplantation

1 reference

12 December 2020

Cardiac sympathetic denervation in familial amyloid polyneuropathy assessed by iodine-123 metaiodobenzylguanidine scintigraphy and heart rate variability

1 reference

12 December 2020

10.1007/S11910-013-0435-3

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1033975731

0 references

1 reference